Ken Griffin Satsuma Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.7 - $1.07 $3,160 - $4,831	-4,515 Reduced 45.55%	5,397 $3,000
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $6,046 - $50,154	9,912 New	9,912 $8,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $89,759 - $149,020	-34,656 Reduced 18.67%	150,954 $624,000
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $3.36 Million - $4.73 Million	-890,010 Reduced 82.74%	185,610 $706,000
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $12,474 - $18,757	3,006 Added 0.28%	1,075,620 $4.84 Million
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $700,149 - $1.11 Million	-154,218 Reduced 12.57%	1,072,614 $5 Million
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $51,196 - $77,328	-10,666 Reduced 0.86%	1,226,832 $8.65 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $3.99 Million - $6.27 Million	872,713 Added 239.24%	1,237,498 $7.31 Million
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $80,199 - $114,667	-22,528 Reduced 5.82%	364,785 $1.68 Million
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $2.47 Million - $18.2 Million	-640,807 Reduced 62.33%	387,313 $1.51 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $123,325 - $267,217	7,703 Added 0.75%	1,028,120 $29.6 Million
Q1 2020 May 15, 2020	BUY	$14.53 - $30.69 $42,645 - $90,075	2,935 Added 0.29%	1,020,417 $22 Million
Q4 2019 Feb 14, 2020	BUY	$9.32 - $19.68 $550,812 - $1.16 Million	59,100 Added 6.17%	1,017,482 $20 Million
Q3 2019 Nov 14, 2019	BUY	$14.98 - $16.9 $14.4 Million - $16.2 Million	958,382 New	958,382 $14.4 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.